Fortress Biotech, Inc. FBIO NASDAQ · Healthcare · United States
$1.88 -5.53% -$0.11
Summary
64 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 143 USD is left as net profit.
- It holds more cash than debt: $152.2M against $39.0M.
- The share price is below the Bulios Fair Price.
What to watch
- Revenue fell by 5.8% a year over the last 3 years.
- Its last loss-making year was 2 years ago.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 0.6 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.8% a year over 5 years. Over the last 3 years it fell by 5.8% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 37 USD
- Research and development 3.8 USD
- Sales and administration 102 USD
- Taxes and other -186 USD
- Net profit 143 USD
Net profit, industry median (Biotechnology) -11 USD
Out of every 100 USD of revenue, 143 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $5 is 166% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Qbrexza 49%
- Accutane 38%
- Amzeeq 9.8%
- Zilxi 3.2%
By region
The company reports no revenue by region.
Qbrexza brings in 49% of revenue. Accutane grew fastest, by 25% a year.
Segments in detail